Dexcom's CGM and Abbott's FreeStyle Libre are ... there's no need for frequent finger sticking. However, some CGM models ...

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...

DexCom reported mixed earnings ... JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed ...

Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Two excellent examples are DexCom (NASDAQ: DXCM) and Vertex Pharmaceuticals (NASDAQ: VRTX). EDINBURGH, Scotland & SAN DIEGO, March 19, 2025--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company. It focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems.

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the positions showed up on publicly available ...

HCPs see CGM as the 'standard of care': Half of all HCPs felt CGM should be the standard of care for people with Type 2 diabetes whether they were using insulin to manage the condition or not. 96% of ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...